Want to see APGE full AI Analyst Report?
Total Valuation
Apogee Therapeutics has a market cap or net worth of $10.18B. The enterprise value is $9.15K.
Market Cap$10.18B
Enterprise Value$9.15K
Share Statistics
Apogee Therapeutics has 62,201,090 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding62,201,090
Owned by Insiders5.56%
Owned by Institutions7.48%
Financial Efficiency
Apogee Therapeutics’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is -31.29%.
Return on Equity (ROE)-0.28
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)-31.29%
Return on Capital Employed (ROCE)-0.31
Revenue Per Employee0.00
Profits Per Employee-980.24K
Employee Count261
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Apogee Therapeutics is ―. Apogee Therapeutics’s PEG ratio is -0.64.
PE Ratio―
PS Ratio0.00
PB Ratio5.07
Price to Fair Value5.07
Price to FCF-19.69
Price to Operating Cash Flow-41.62
PEG Ratio-0.64
Income Statement
In the last 12 months, Apogee Therapeutics had revenue of 0.00 and earned -255.84M in profits. Earnings per share was -4.22.
Revenue0.00
Gross Profit-1.42M
Operating Income-285.60M
Pretax Income-255.56M
Net Income-255.84M
EBITDA-254.15M
Earnings Per Share (EPS)-4.22
Cash Flow
In the last 12 months, operating cash flow was -243.89M and capital expenditures -62.00K, giving a free cash flow of -243.96M billion.
Operating Cash Flow-243.89M
Free Cash Flow-243.96M
Free Cash Flow per Share-3.92
Dividends & Yields
Apogee Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.74
52-Week Price Change264.63%
50-Day Moving Average123.51
200-Day Moving Average86.93
Relative Strength Index (RSI)76.23
Average Volume (3m)4.35M
Important Dates
Apogee Therapeutics upcoming earnings date is Nov 16, 2026, Before Open (Confirmed).
Last Earnings DateAug 10, 2026
Next Earnings DateNov 16, 2026
Ex-Dividend Date―
Financial Position
Apogee Therapeutics as a current ratio of 26.57, with Debt / Equity ratio of 0.57%
Current Ratio26.57
Quick Ratio26.57
Debt to Market Cap<0.01
Net Debt to EBITDA0.48
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Apogee Therapeutics has paid 278.00K in taxes.
Income Tax278.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Apogee Therapeutics EV to EBITDA ratio is -17.54, with an EV/FCF ratio of -19.17.
EV to Sales0.00
EV to EBITDA-17.54
EV to Free Cash Flow-19.17
EV to Operating Cash Flow-19.60
Balance Sheet
Apogee Therapeutics has $971.93M in cash and marketable securities with $6.83M in debt, giving a net cash position of $965.09M billion.
Cash & Marketable Securities$971.93M
Total Debt$6.83M
Net Cash$965.09M
Net Cash Per Share$15.52
Tangible Book Value Per Share$14.89
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Apogee Therapeutics is $131.18, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$131.18
Price Target Upside-2.31% Downside
Analyst ConsensusHold
Analyst Count15
Revenue Growth Forecast―
EPS Growth Forecast-6.36%